Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Why the study?
Does dual therapy with dabigatran and a P2Y12 inhibitor reduce the risk of bleeding in patients with atrial fibrillation who had undergone PCI?
Population
Patients with atrial fibrillation who had undergone PCI
Comparison
Dual therapy with dabigatran and a P2Y12 inhibitor vs Triple therapy with warfarin, a P2Y12 inhibitor…
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Supports dual dabigatran therapy post-PCI in AF to reduce bleeding; confirms noninferior thromboembolic protection versus triple therapy.
Key Points
- This research aims to compare the bleeding risk and thromboembolic event rates between dual and triple antithrombotic therapy in atrial fibrillation patients after PCI.
- Randomized trial of dual therapy with dabigatran and P2Y12 inhibitor versus triple therapy with warfarin, P2Y12 inhibitor, and aspirin.
- Patients included had atrial fibrillation and underwent PCI.
- Trial registration number: NCT02164864.
- Dual therapy associated with a lower risk of bleeding compared to triple therapy (exact rates not specified).
- Dual therapy shown to be noninferior to triple therapy regarding thromboembolic events (specific metrics not detailed).
Structured PICO
Does dual therapy with dabigatran and a P2Y12 inhibitor reduce the risk of bleeding in patients with atrial fibrillation who had undergone PCI?
P
Population
Patients with atrial fibrillation who had undergone PCI
I
Intervention
Dual therapy with dabigatran and a P2Y12 inhibitor
C
Comparator
Triple therapy with warfarin, a P2Y12 inhibitor, and aspirin
O
Outcome
Risk of bleedingsafety
In patients with atrial fibrillation undergoing PCI, dual antithrombotic therapy with dabigatran reduces bleeding risk compared to triple therapy with warfarin, without compromising protection against thromboembolic events.
Cite This Study
Cannon et al. (2017) studied this question.